Around 200,000 Indian households are currently using GLP-1 medications to manage diabetes and obesity, according to an estimate by PwC, highlighting the rapid emergence of a new market for weight-management and metabolic health treatments. Drugs such as Ozempic and Mounjaro are gaining traction among consumers, particularly in India’s major metropolitan cities, as demand for medical weight-loss solutions and diabetes management continues to increase.

The growing adoption of GLP-1 drugs is creating new opportunities for pharmaceutical companies, healthcare providers and consumer health businesses. PwC estimates that households using these medicines spend between ₹8,000 and ₹16,000 per month, with the number of users reportedly doubling annually. However, the market is also facing questions around affordability, prescription access, long-term treatment costs and the sustainability of demand as more products enter the Indian pharmaceutical market.

200,000 Indian Households Are Using GLP-1 Medications

PwC estimates that approximately two lakh Indian households are currently using GLP-1 drugs to manage diabetes or obesity.

The consultancy said a significant proportion of users are concentrated in India’s top five or six metropolitan cities, reflecting the greater availability of healthcare services, specialist doctors, pharmacies and awareness of newer weight-management treatments in urban markets.

The estimate is based on household usage rather than individual patients because multiple members of the same family may be using these medicines simultaneously.

The number of households using GLP-1 drugs is reportedly doubling every year, indicating growing adoption as awareness of the treatment category expands.

However, the estimate represents households using these medicines and should not be interpreted as an exact count of individual patients.

Households Spend ₹8,000–₹16,000 Every Month on GLP-1 Drugs

The growing popularity of GLP-1 medications is creating a significant recurring expenditure for Indian households.

According to PwC, households using these drugs spend approximately ₹8,000 to ₹16,000 per month on medication. The medicines are prescription-based and are generally used under medical supervision.

The monthly spending range highlights the financial commitment required for patients who continue treatment over extended periods.

Market indicatorPwC estimate
Indian households using GLP-1 drugs200,000
Monthly spending per household₹8,000–₹16,000
Estimated annual spending per household₹96,000–₹1.92 lakh
Annual spending across 200,000 households₹1,920 crore–₹3,840 crore
Estimated annual growth in household adoptionDoubling

The spending figures illustrate the potential scale of the market, although the aggregate estimates are calculated by multiplying the reported household count by the spending range and do not represent an independently measured market revenue figure.

Ozempic and Mounjaro Drive India’s GLP-1 Market

GLP-1 medications were originally developed primarily to help manage type 2 diabetes but have also become increasingly associated with obesity treatment and weight management.

The drugs work by mimicking hormones involved in regulating blood sugar, appetite and food intake. Depending on the medicine, they can help patients manage glucose levels and reduce appetite, potentially contributing to weight loss.

Products such as Ozempic and Mounjaro have gained global attention as pharmaceutical companies expand their diabetes and obesity treatment portfolios.

India’s market is becoming more competitive as pharmaceutical companies introduce new products and generic alternatives, potentially increasing access to treatment while putting pressure on prices.

The availability of approximately 20 brands in the Indian market, as cited by PwC, reflects the growing commercial interest in the category.

India’s GLP-1 Market Could Expand Rapidly

India has a large potential market for diabetes and obesity treatments because of the country’s significant burden of metabolic diseases, changing lifestyles and increasing awareness of weight-related health risks.

The introduction of more affordable medicines could expand access beyond wealthy urban consumers, although affordability remains a major barrier for many households.

Industry analysts have also projected substantial growth in India’s GLP-1 market over the coming years as adoption rises and competition increases.

The potential market is attracting interest from pharmaceutical companies, healthcare providers, distributors and consumer health businesses seeking to participate in the growing demand for metabolic health solutions.

The market’s expansion, however, will depend on factors such as doctors’ recommendations, treatment affordability, patient adherence, clinical outcomes, regulatory oversight and long-term demand.

Generic Drugs Could Change the Market

The entry of generic semaglutide products in India has the potential to reshape the economics of the GLP-1 market.

Lower-priced alternatives could make treatment more accessible to patients who previously found branded medicines too expensive. Competition among pharmaceutical companies could also lead to price reductions, new distribution models and broader availability.

For drug manufacturers, the market offers opportunities to capture a growing patient population. For consumers, greater competition could improve affordability, although pricing differences between products, dosage requirements and treatment plans may continue to influence monthly costs.

The emergence of generic medicines could become one of the most important drivers of GLP-1 adoption in India, particularly if prices decline significantly over time.

PwC Survey Highlights India’s Growing Focus on Wellness

Alongside its GLP-1 estimates, PwC released findings from a survey of 1,005 respondents highlighting the growing importance of health and well-being among Indian consumers.

The survey found that 97% of respondents wanted to prioritise long-term well-being. However, 67% said stress, fatigue or low energy were barriers preventing them from maintaining healthy everyday routines.

Factors such as traffic, family responsibilities, time constraints and demanding lifestyles can make it difficult for individuals to consistently prioritise exercise, nutrition and other wellness activities.

The findings suggest that health-conscious consumers are increasingly looking for solutions that fit into their daily lives, including healthcare services, wellness products, nutrition-focused foods and medical treatments.

The survey also highlighted growing concerns among Indian consumers about microplastics, protein intake, fibre consumption and calorie intake.

Pharmaceutical Companies See a Major Opportunity

The rapid growth of GLP-1 medicines is creating opportunities across India’s pharmaceutical and healthcare ecosystem.

Drug manufacturers could benefit from rising demand, particularly as the market expands beyond a relatively small group of high-income consumers.

Healthcare providers may see increased demand for consultations related to diabetes, obesity, metabolic health and long-term weight management.

Pharmacies, healthcare delivery platforms and digital health businesses could also benefit from the growing need for prescription medicines, patient support services and treatment monitoring.

However, the opportunity comes with challenges. Companies will need to ensure medicines are distributed responsibly, prescriptions are handled appropriately and patients receive adequate medical guidance.

The commercial success of GLP-1 drugs will also depend on whether patients can afford to continue treatment over longer periods rather than using the medicines only temporarily.

The Bigger Picture

India’s GLP-1 market is emerging at the intersection of healthcare, pharmaceuticals, consumer behaviour and lifestyle changes.

The PwC estimate of 200,000 households highlights the growing adoption of medicines associated with diabetes and obesity treatment, while the reported doubling in usage suggests the category is gaining momentum.

The market could expand significantly as more pharmaceutical companies enter, generic alternatives become available and awareness of metabolic health increases.

At the same time, the growing popularity of these drugs underscores the importance of medical supervision, affordability and sustainable healthcare solutions. GLP-1 medicines are prescription treatments and are not substitutes for professional medical advice or appropriate lifestyle management.

Looking Ahead

The number of Indian households using GLP-1 drugs could continue increasing as awareness grows, pharmaceutical competition expands and more affordable products become available. India’s major metropolitan markets are likely to remain important centres of adoption initially, while lower prices could gradually broaden access to consumers in other cities. The industry’s ability to sustain growth will depend on treatment affordability, medical guidance, patient adherence and confidence in the products available.

For pharmaceutical companies, the GLP-1 category could become one of India’s most significant emerging healthcare markets. The combination of a large diabetes and obesity patient population, rising health awareness, new medicines and generic competition creates substantial commercial potential. However, long-term market growth will ultimately depend on responsible prescribing, clinical benefits, access to healthcare and the ability of households to sustain treatment costs.

Get the day’s top stories in your inbox

One concise email. No spam, unsubscribe anytime.